Toichi Takino
Profile
Performance in office
Tenure
Tenure
Background
He joined Ono Pharmaceutical in April 1995. He became an Executive Officer in June 2011, Managing Executive Officer in June 2019, Director and Managing Executive Officer in June 2020 and Director and Senior Managing Executive Officer in June 2021, and took office as Representative Director, President and COO in April 2024. It was 29 years from joining to the presidency, longer than the 25 years of his predecessor Gyo Sagara, and four years from joining the board.
Selection
In April 2024 he became Representative Director, President and COO, succeeding Gyo Sagara, who moved to Representative Director, Chairman and CEO. In the fiscal year ended March 2024, the year before he took office, revenue was ¥502.7 billion and operating income ¥159.9 billion, more than three times the scale of ¥143.2 billion and ¥26.4 billion in FY ended March 2014. The appointment appears to have handed him the role of carrying the expanded earnings over to the next products.
Initiatives
In 2024, the same year he took office, the company acquired Deciphera Pharmaceuticals of the US for about $2.4 billion, gaining a sales network in Europe and the US. In the fiscal year ended March 2025 revenue was ¥486.9 billion and operating income ¥59.7 billion, down from ¥502.7 billion and ¥159.9 billion the year before. In FY ended March 2026 they recovered to revenue of ¥515.8 billion and operating income of ¥92.2 billion.
Career
Career
Ono Pharmaceutical
| Date | Position |
|---|---|
| Apr 1995 | Joined |
| Jun 2011 | Executive Officer |
| Jun 2019 | Managing Executive Officer |
| Jun 2020 | Director, Managing Executive Officer |
| Jun 2021 | Director, Senior Managing Executive Officer |
| Apr 2024 | Representative Director, President, COO |
References 1
References (Japanese primary sources)
- 小野薬品工業 有価証券報告書【役員の状況】